白术芍药散联合美沙拉嗪肠溶片治疗溃疡性结肠炎的临床疗效分析

Clinical Effect Analysis on Ulcerative Colitis Treated with Baizhu Shaoyao San Combined with Mesalazine Enteric-coated Tablets

为探讨白术芍药散联合美沙拉嗪肠溶片治疗溃疡性结肠炎(UC)的临床疗效,将2018年8月至2019年8月我科收治的106例UC患者随机分为观察组和对照组,各53例,对照组患者单纯口服美沙拉嗪肠溶片治疗,观察组在对照组治疗基础上口服白术芍药散煎剂。治疗8周后,比较2组临床总体疗效及疾病活动性(Mayo评分)。结果显示,1)临床总体疗效:观察组治疗总有效率(96.23%,51/53)明显高于对照组(77.36%,41/53),P<0.05。2)疾病活动性:2组患者治疗前Mayo评分比较差异无统计学意义,P>0.05;治疗后2组Mayo评分均明显降低,P<0.05;治疗后2组间比较,观察组Mayo评分明显低于对照组,P<0.05。结果表明,与单纯口服美沙拉嗪肠溶片相比,联合白术芍药散煎剂口服治疗UC可提高临床治疗效果,值得临床推广应用。

This study was to investigate the clinical effect of ulcerative colitis(UC)treated with Baizhu Shaoyao San(San)and Mesalazine enteric-coated tablets(Tablets),randomly divided 106UC patients treated in authors'department(2018-08-2019-08)into control group(53cases,orally administered Tablets)and observation group(53cases,Tablets plus San),at 8weeks after treatment compared both groups'clinical whole effect and DAI Mayo score.As results,1)the total effective rate of observation group was significantly higher than that of control group[96.23%(51/53)vs 77.36%(41/53),P<0.05];2)before treatment Mayo score had no statistical difference between the two groups(P>0.05),but after one both groups'Mayo score was all significantly declined(P<0.05),and the score of observation group was significantly lower than that of control group(P<0.05).Results show that San plus Tablets can more enhance clinical effect than alone Tablets.It is worthy of clinical popularization and application.